Next generation relaxin molecular probes and therapeutics

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1117483

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The peptide hormone relaxin is poised to be the first new treatment for acute heart failure in more than 40 years. However, like other therapeutic peptides, it has a very short duration of action due to its rapid clearance by the body. My work will utilize powerful medicinal chemistry methods to develop new analogues of relaxin that have much longer action by complexing it with sugar or making relaxin polymers. I will also produce smaller relaxin analogues that will be cheaper to manufacture.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2021

Funding Scheme: Research Fellowships

Funding Amount: $763,845.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Proteins and Peptides

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cardiovascular disease | drug development | medicinal chemistry | peptide synthesis | peptides

Related Links